A Sativex-Like THC+CBD Combination Partially Protected Against Brain Deterioration in a Mouse Model of Huntington's Disease

R6/2 transgenic mice (Huntington's disease model) and wild-type controls received daily treatment with Sativex-like phytocannabinoid combination or vehicle from week 4. Assessment included behavioral testing, in vivo PET imaging, and ex vivo proton MRS spectroscopy of the striatum.

Huntington's disease has no disease-modifying treatment. While this cannabinoid combination did not reverse the motor deficits, the improvement in dystonia and reversal of metabolic brain changes suggest partial neuroprotective effects that warrant further investigation.

Previous studies showed promising neuroprotective effects of cannabinoids in neurotoxin-based models of Huntington's, but those are simpler models. Testing in the R6/2 genetic model, which better represents the human disease, yielded more modest but still encouraging results. The selective improvement in dystonia without motor coordination improvement suggests cannabinoids may target specific aspects of Huntington's pathology.

Mouse model: R6/2 mice develop severe disease very rapidly (weeks), unlike human Huntington's which progresses over decades. Only one dose and ratio were tested. The motor coordination deficits (rotarod) did not improve, which is the most clinically relevant motor outcome. The metabolic improvements may not translate to functional clinical benefit.